Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
21.92
-0.56 (-2.49%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Bicara Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 30.51 | 18.77 | 9.27 | 6.34 |
| Research & Development | 125.1 | 63.62 | 30.62 | 31.31 |
| Operating Expenses | 155.6 | 82.39 | 39.89 | 37.66 |
| Operating Income | -155.6 | -82.39 | -39.89 | -37.66 |
| Interest Expense | - | - | - | -0.11 |
| Interest & Investment Income | 17.87 | 14.58 | 1.31 | 0 |
| Other Non Operating Income (Expenses) | - | - | -13.41 | -0.08 |
| Pretax Income | -137.73 | -67.81 | -51.98 | -37.84 |
| Income Tax Expense | 0.22 | 0.19 | 0.01 | 0 |
| Net Income | -137.95 | -68 | -51.99 | -37.85 |
| Net Income to Common | -137.95 | -68 | -51.99 | -37.85 |
| Shares Outstanding (Basic) | 55 | 17 | 1 | 0 |
| Shares Outstanding (Diluted) | 55 | 17 | 1 | 0 |
| Shares Change (YoY) | 225.35% | 2796.96% | 35.20% | - |
| EPS (Basic) | -2.52 | -4.05 | -89.61 | -88.20 |
| EPS (Diluted) | -2.52 | -4.05 | -89.61 | -88.20 |
| Free Cash Flow | -107.11 | -74.82 | -46.21 | -32.27 |
| Free Cash Flow Per Share | -1.96 | -4.45 | -79.66 | -75.20 |
| EBITDA | -155.5 | -82.33 | -39.87 | -37.65 |
| D&A For EBITDA | 0.11 | 0.06 | 0.02 | 0.01 |
| EBIT | -155.6 | -82.39 | -39.89 | -37.66 |
Source: S&P Capital IQ. Standard template.
Financial Sources.